Literature DB >> 8777683

Screening for tyrosinaemia type I.

A C Hutchesson1, S K Hall, M A Preece, A Green.   

Abstract

AIMS: To assess the incidence of tyrosinaemia type I in the West Midlands Region, and the value of current neonatal screening programmes for phenylketonuria (PKU) for its detection.
METHODS: Retrospective study of results from the PKU neonatal screening programmes in Birmingham (using plasma amino acid chromatography) and in the rest of the West Midlands (using the Guthrie microbiological assay for blood spot phenylalanine) was carried out between January 1985 and March 1994. Patients with tyrosinaemia I born in the region during the same period were identified from a regional database of patients with confirmed inherited metabolic disease. The study was carried out in a specialist children's hospital; the regional centre in the West Midlands for neonatal screening and investigation of inborn errors, and a supraregional centre for liver transplantation and management of paediatric liver disease.
RESULTS: Amino acid chromatography showed increased tyrosine in 447 of 145,444 neonates born in Birmingham; this was still increased at 6 weeks of age in six cases. Five had tyrosinaemia I; the sixth had tyrosinaemia type III. Two others in whom amino acid chromatography was considered normal have since presented with tyrosinaemia I. Outside Birmingham, 525,151 children were screened using the Guthrie test. Five have presented clinically with tyrosinaemia I; screening did not contribute to diagnosis in any case. The incidence of tyrosinaemia I was 1 in 20,791 live births within Birmingham and 1 in 105,037 outside. Of the total 12 patients in the West Midlands with tyrosinaemia I, 10 (83%) were of non-oriental Asian ethnicity; the incidence of tyrosinaemia I was 3.7/10(6) head of population in this group and 0.04/10(6) in the rest of the population.
CONCLUSIONS: Asians in the West Midlands have a high incidence of tyrosinaemia I. Neonatal PKU screening using amino acid chromatography may contribute to diagnosis and early treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777683      PMCID: PMC2528336          DOI: 10.1136/fn.74.3.f191

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  15 in total

1.  Neonatal screen for hereditary tyrosinaemia type I.

Authors:  E Holme; S Lindstedt
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

2.  APPLICATION OF A SIMPLE MICROMETHOD TO THE SCREENING OF PLASMA FOR A VARIETY OF AMINOACIDOPATHIES.

Authors:  C R SCRIVER; E DAVIES; A M CULLEN
Journal:  Lancet       Date:  1964-08-01       Impact factor: 79.321

3.  Tyrosinaemia type I with normal levels of plasma tyrosine.

Authors:  I T de Almeida; P P Leandro; M F Silva; C Silveira; A da Silva; J S de Sousa; M Duran
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  Experience with 37 infants with tyrosinemia.

Authors:  J Larochelle; A Mortezai; M Belanger; M Tremblay; J C Claveau; G Aubin
Journal:  Can Med Assoc J       Date:  1967-10-28       Impact factor: 8.262

5.  Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.

Authors:  A Grenier; A Lescault; C Laberge; R Gagné; O Mamer
Journal:  Clin Chim Acta       Date:  1982-08-04       Impact factor: 3.786

6.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  S Lindstedt; E Holme; E A Lock; O Hjalmarson; B Strandvik
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

Review 7.  Organ transplantation for inherited metabolic disease.

Authors:  D A Kelly
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

8.  A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.

Authors:  M Grompe; M St-Louis; S I Demers; M al-Dhalimy; B Leclerc; R M Tanguay
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

9.  Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I.

Authors:  C Laberge; A Grenier; J P Valet; J Morissette
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

Review 10.  Tyrosinaemia type I--an update.

Authors:  E A Kvittingen
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

View more
  9 in total

1.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

2.  Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.

Authors:  Bijo Varughese; Dnyanoba Madrewar; Sunil Kumar Polipalli; Seema Kapoor
Journal:  Indian J Clin Biochem       Date:  2021-01-06

3.  A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK.

Authors:  A C Hutchesson; S Bundey; M A Preece; S K Hall; A Green
Journal:  J Med Genet       Date:  1998-05       Impact factor: 6.318

4.  Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.

Authors:  David C Bartlett; Carla Lloyd; Patrick J McKiernan; Phil N Newsome
Journal:  J Inherit Metab Dis       Date:  2014-02-11       Impact factor: 4.982

5.  Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

Authors:  David C Bartlett; Mary Anne Preece; Elisabeth Holme; Carla Lloyd; Phil N Newsome; Patrick J McKiernan
Journal:  J Inherit Metab Dis       Date:  2012-03-29       Impact factor: 4.982

6.  Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1.

Authors:  Nathalie Guffon; Anders Bröijersén; Ingrid Palmgren; Mattias Rudebeck; Birgitta Olsson
Journal:  JIMD Rep       Date:  2017-06-23

Review 7.  Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.

Authors:  Chris Stinton; Julia Geppert; Karoline Freeman; Aileen Clarke; Samantha Johnson; Hannah Fraser; Paul Sutcliffe; Sian Taylor-Phillips
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

8.  Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.

Authors:  Iratxe Macias; Ana Laín; Ganeko Bernardo-Seisdedos; David Gil; Esperanza Gonzalez; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2019-07-12       Impact factor: 5.157

9.  Inter-laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples.

Authors:  Hilde Laeremans; Charles Turner; Tommy Andersson; Jose Angel Cocho de Juan; Adam Gerrard; M Rebecca Heiner-Fokkema; Diran Herebian; Nils Janzen; Giancarlo la Marca; Mattias Rudebeck
Journal:  JIMD Rep       Date:  2020-04-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.